In June 2017, the Indian pharmaceutical market experienced a steady growth rate of 7.5% ahead of the GST implementation, with a notable focus on chronic and sub-chronic medication categories. The data indicates that the top 10 companies account for 42.75% of the market share, while Indian companies are performing better than multinational corporations in terms of growth. The anti-diabetic sector was highlighted for its substantial incremental value contribution to the market during this period.

1. Dataset : PharmaTrac MAT JUN 2017
PharmaTrac Overview
JUN 17

2. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
INDUSTRY DYNAMICS: Market at 7.5% in June-17 the growth has held steady
in run up to GST implementation….
7084
7149
7078
7595
7543
8063
7294
7539
7620
7533
7450
7624
8337
8016
8158
8549
8544
8874
8900
8263
8606
8350
8489
8265
8828
8790
8801
9508
10031
10096
9690
9478
9247
9129
9047
9081
9551
9416
9463
17.7
12.1
15.3
12.6
13.3
10.1
22.0
9.6
12.9
10.9
13.9
8.4
5.9
9.7
7.9
11.2
17.4
13.8
8.9
14.7
7.5
9.3
6.6
9.9
8.2
7.1 7.5
0.0
5.0
10.0
15.0
20.0
25.0
30.0
0
2000
4000
6000
8000
10000
12000
APR MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB MAR
Indian Pharma Market Trends - 2014-2018
2014-2015 2015-2016 2016-2017 2017-2018 GR % 2015-2016 GR % 2016-2017 GR % 2017-2018

3. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
QOQ DYNAMICS: Q2 - 17 growth at 7.6%......... Growth holding steady in
the pre GST implementation period. Chronic port folio driven growth
Q 1 14 Q2 14 Q3 14 Q4 14 Q 1 15 Q 2 15 Q 3 15 Q 4 15 Q 1 16 Q 2 16 Q 3 16 Q 4 16 Q 1 17 Q 2 17
INCRE 1344 1929 2769 2208 3205 3201 2767 3316 2497 1907 3668 2647 2154 2012
19402
21310
23200
22453 22607
24512
25967 25769 25104
26418
29635
28415
27258 28431
7.4
10.0
13.6
10.9
16.5
15.0
11.9
14.8
11.0
7.8
14.1
10.3
8.6
7.6
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
18.0
20.0
0
5000
10000
15000
20000
25000
30000
35000
VALUE GR

4. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
7 Corporates in double digit growths for MAT. Glaxo showing a positive MAT
growth after struggling for over a year. Lupin and Zydus and Macleods showing
higher quarterly growths
9584
6883
5051 4637
3625 3673 3726
3340
2978
3081
142
133
257
340
555
250
56
75 254 42
11.3
10.0
6.9
16.8
9.1
10.6
12.7
2.3
11.2
10.5
7.8
7.2
2.6
17.5
10.2
0.0
13.4
8.6
11.2
2.9
0
2
4
6
8
10
12
14
16
18
20
0
2000
4000
6000
8000
10000
12000
SUN* ABBOTT* CIPLA ZYDUS* MANKIND ALKEM* LUPIN GSK MACLEODS INTAS
AV BV GR RUN-QTR GR JUN 17

5. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
ACUTE/CHRONIC SPLIT: Chronic and Sub chronic categories driving growth
GR
IPM SUN* ABBOTT* CIPLA ZYDUS* MANKIND ALKEM* LUPIN GSK MACLEODS INTAS
11.2 15.6 14.0 14.4 14.0 12.2 12.6 3.3 6.2 21.8 22.6
12.0 15.0 10.5 11.7 11.0 16.7 15.7 17.0 2.5 3.7 6.0
8.5 5.9 7.4 0.9 21.7 5.0 9.1 11.8 1.0 11.9 10.5
48
39 38
44
51 55
64
32
65
48
25
32 47
41
43 31 25 11
51
13
30
53
20
14
20
13
18 19
25
18 22 21 22
IPM SUN* ABBOTT* CIPLA ZYDUS* MANKIND ALKEM* LUPIN GSK MACLEODS INTAS
ACUTE CHRONIC SUB CHRONIC

6. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
RANK SPLIT: Top 10 Contribute 42.75% to the IPM. Smaller and tail-
ender companies growing slower than the market
Jun-16 Jun-17
MAT VAL MS GR CORPORATE MAT VAL MS GR
103258 100.00 11.3 IPM 113739 100.00 10.1
44146 42.75 11.1 TOP 10 48682 42.80 10.3
28385 27.49 11.4 11-25 31465 27.66 10.9
14294 13.84 16.0 26 - 50 15798 13.89 10.5
10164 9.84 7.0 51 - 100 11135 9.79 9.5
6269 6.07 9.3 100 + 6660 5.86 6.2
42.75
27.49
13.84
9.84 6.07
JUN-16
TOP 10 11 - 25 26 - 50 51 - 100 100 +
42.80
27.66
13.89
9.79 5.86
JUN-17
TOP 10 11 - 25 26 - 50 51 - 100 100 +

7. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
INDIAN/MNC SPLIT: Indian Companies dominate & are growing above the
Market on MAT basis. However for the Month June-17 MNC collectively
growing better than Indian companies
GR VAL : 10.8 GR VAL : 7.7IPM GR VAL : 10.1
0200040006000800010000
SUN*,
9726
CIPLA,
5308
ZYDUS*,
4977
MANKIN
D, 4180
ALKEM*,
3924
79.08
20.92
INDIAN MNC
0 2000 4000 6000 8000
ABBOTT*,
7015
GSK, 3415
PFIZER*,
2846
SANOFI
INDIA,
2534
NOVARTIS,
1075

8. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
* Abbott + Abbott HC + Novo; Alkem + Indchemie + Cachet; Pfizer + Wyeth; Zydus + Biochem; Micro + Bal
ZONAL SPLIT: South dominates rest of the zones growing slower
than the IPM
26.8%
25.8%
20.1%
23.5%
JUN-17
20.1%
23.5%
20.2% 26.5%
22.4% 25.8%
20.2% 26.7%
22.1% 25.6%
SOUTH ZONE
NORTH ZONE
WEST ZONE
EAST ZONE
ZONE
JUN-16
MAT VAL JUN 17
ZONE MAT VAL MS MS (G / L) GR INCRE VAL
IPM 113739 100.00% 0.00% 10.1 10480
SOUTH ZONE 30421 26.75% 0.21% 11.0 3024
NORTH ZONE 29088 25.57% -0.24% 9.1 2429
WEST ZONE 25181 22.14% -0.24% 9.0 2074
EAST ZONE 22959 20.19% -0.04% 9.9 2076
ALL INDIA ONLY 6089 5.35% 0.31% 16.8 877

9. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
Top 3 Markets constitutes 38.2% of IPM…….Anti-Diabetics adds Maximum
incremental value on MAT basis, followed by Anti-infectives and CVS….
MAT VAL JUN 17 MS
SUPERGROUP SV BV GR INCRE VAL BV % TO SV SV BV
IPM 113739 4273 10.1 10480 3.8 100.00 100.00
ANTI-INFECTIVES 16217 1255 4.6 708 7.7 14.26 29.37
CARDIAC 14025 122 11.4 1433 0.9 12.33 2.84
GASTRO INTESTINAL 13198 464 9.9 1184 3.5 11.60 10.87
ANTI DIABETIC 10148 82 19.2 1637 0.8 8.92 1.91
VITAMINS / MINERALS / NUTRIENTS 9951 278 8.6 786 2.8 8.75 6.51
RESPIRATORY 8478 351 9.4 727 4.1 7.45 8.21
PAIN / ANALGESICS 7832 347 9.8 699 4.4 6.89 8.12
DERMA 6859 209 12.7 772 3.1 6.03 4.90
NEURO / CNS 6847 79 8.4 533 1.2 6.02 1.86
GYNAECOLOGICAL 5926 479 11.1 594 8.1 5.21 11.22
ANTI-NEOPLASTICS 2391 5 7.2 160 0.2 2.10 0.12
VACCINES 2131 117 20.3 360 5.5 1.87 2.74
OPHTHAL / OTOLOGICALS 2085 31 6.4 126 1.5 1.83 0.72
HORMONES 1918 16 9.0 159 0.8 1.69 0.38
BLOOD RELATED 1436 32 14.2 178 2.2 1.26 0.74
UROLOGY 1318 23 11.5 136 1.8 1.16 0.55
OTHERS 1241 48 16.1 172 3.9 1.09 1.12
SEX STIMULANTS / REJUVENATORS 653 230 16.9 94 35.3 0.57 5.39
ANTI MALARIALS 586 91 -1.0 -6.0 15.5 0.52 2.13
STOMATOLOGICALS 499 13 5.5 26 2.6 0.44 0.30

10. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
Mixtard leads………..6 out of top 20 Anti-diabetic……………Three brands
adding 90Crs or more amongst top 10
RANK Jun-17
Jun-17 G/L BRAND SUBGROUP CORPORATE SV AV BV GR INCRE
0 0 IPM 113739 109466 4273 10.1 10480
1 0 MIXTARD HUMAN PREMIX ABBOTT* 517 511 6 6.1 30
2 1 GLYCOMET GP GLIMEPIRIDE + METFORMIN USV 433 424 9 26.4 90
3 2 SPASMO PROXYVON PLUS DICYCLOMINE + PARACETAMOL + TRAMADOL WOCKHARDT 422 422 1 32.1 103
4 3 GALVUS MET VILDAGLIPTIN + METFORMIN NOVARTIS 362 353 8 24.7 72
5 5 LANTUS GLARGINE SANOFI INDIA 340 336 3 27.1 72
6 6 JANUMET SITAGLIPTIN + METFORMIN MSD* 310 309 1 24.4 61
7 2 LIV 52 HEPATIC PROTECTORS INCLUDING AYURVEDIC HIMALAYA 296 294 2 9.2 25
8 -2 AUGMENTIN AMOXYCILLIN + CLAVULANIC ACID GSK 295 293 1 -2.5 -8
9 15 NOVOMIX BIPHASIC ASPART ABBOTT* 284 283 1 49.7 94
10 1 CLAVAM AMOXYCILLIN + CLAVULANIC ACID ALKEM* 280 242 39 10.4 26
11 -3 MONOCEF CEFTRIAXONE ARISTO 278 215 63 1.4 4
12 9 SYNFLORIX ALL OTHER VACCINES GSK 252 230 22 27.0 54
13 4 PAN PANTOPRAZOLE ALKEM* 251 245 6 19.4 41
14 11 HEPCINAT SOFOSBUVIR NATCO 250 237 14 35.0 65
15 -1 VOLINI DICLOFENAC SUN* 240 223 17 4.4 10
16 4 FORACORT FORMOTERAL + BUDESONIDE CIPLA 231 228 3 15.0 30
17 6 VOVERAN DICLOFENAC NOVARTIS 227 213 14 14.9 29
18 16 DUPHASTON DYDROGESTERONE ABBOTT* 226 222 4 29.2 51
19 -3 BECOSULES VITAMIN B COMPLEX WITH VITAMIN C ONLY PFIZER* 224 216 8 2.2 5
20 -5 ACILOC RANITIDINE CADILA 223 219 4 -2.7 -6

11. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
69 Brands cross 10 Crs launched……….64 NIs in Itraconazole & more than 100
brands launched in Teneligliptin and combinations segment
Jun-17
BRAND SUBGROUP COMPANY LD MAT VAL INCRE VAL
NI BRANDS(LAST 24 MONTHS) 4525 3344
HEXAXIM COMBINATIONS WITH TETANUS COMPONENT SANOFI INDIA Oct-16 112 112
PANDERM NM CLOBETASOL + NEOMYCIN + MICONAZOLE MACLEODS May-16 104 93
HEPCINAT LP SOFOSBUVIR + LEDIPASVIR NATCO Jan-16 99 -72
JARDIANCE EMPAGLIFLOZIN BOEHRINGER INGELHEIM Oct-15 94 72
NATDAC DACLATASVIR NATCO May-16 81 79
VIVITRA TRASTUZUMAB ZYDUS* Jan-16 71 58
IT-MAC ITRACONAZOLE MACLEODS Oct-15 55 44
AXCER TICAGRELOR SUN* Oct-15 55 42
ZITAMET PLUS TENELIGLIPTIN + METFORMIN GLENMARK Oct-15 47 28
INSTA MIFEPRISTONE + MISOPROSTOL MACLEODS Apr-16 40 29
SULISENT CANAGLIFLOZIN USV Oct-15 40 27
ONDERO LINAGLIPTIN LUPIN Nov-15 40 29
DECA DURABOLIN NANDROLONE ZYDUS* Jan-17 34 34
BGR 34 AYURVEDIC AIMIL Oct-15 31 15
ONDERO MET LINAGLIPTIN + METFORMIN LUPIN Mar-16 30 27
TENGLYN TENELIGLIPTIN ZYDUS* Nov-15 29 16
PRIORIX TETRA
COMBINATIONS WITH MEASLES AND / OR
MUMPS (E.G. MMR)
GSK Jul-16 29 29
ZITEN M TENELIGLIPTIN + METFORMIN GLENMARK Oct-15 28 18
AMBRODIL S PLUS LEVOSALBUTAMOL + AMBROXOL ARISTO Aug-16 28 28
CEREBROLYSIN CEREBROPROTEIN HYDROLYSATE SUN* Jul-15 27 5

12. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
6325 Brands launched in last 24 months…
Jun-17
BRAND SUBGROUP COMPANY LD MAT VAL INCRE VAL
NI BRANDS(LAST 24 MONTHS) 4525 3344
CARIPILL CARICA PAPAYA COMBINATIONS MICRO* Jul-15 27 11
NICOTEX PLUS NICOTINE CIPLA Aug-15 24 14
LUPIHEME ELEMENTAL IRON LUPIN Sep-15 21 14
GIBTULIO EMPAGLIFLOZIN LUPIN Sep-16 21 21
DYNAGLIPT TENELIGLIPTIN MANKIND Nov-15 20 14
TENEPRIDE TENELIGLIPTIN MICRO* Nov-15 20 12
DACIHEP DACLATASVIR ZYDUS* Dec-15 20 14
GESTAREST MIFEPRISTONE + MISOPROSTOL MACLEODS Mar-16 17 12
SINAREST NEW PARACETAMOL + PHENYLEPHRINE + CHLORPHENIRAMINE CENTAUR May-16 17 17
LULICAN LULICONAZOLE GLENMARK Jul-16 17 17
OXRA DAPAGLIFLOZIN SUN* Aug-16 17 17
LULIBET LULICONAZOLE INTAS Jul-16 17 17
TENDIA TENELIGLIPTIN KINEDEX Oct-15 17 10
TERBINAFORCE LITE CLOTRIMAZOLE + CLOBETASOL + NEOMYCIN MANKIND Jul-16 16 16
TENDIA M TENELIGLIPTIN + METFORMIN KINEDEX Mar-16 16 14
NOVOGERMINA BACILLUS CLAUSII ALKEM* Apr-16 16 14
RESOF L SOFOSBUVIR + LEDIPASVIR DR. REDDYS Dec-15 15 12
LEDIHEP SOFOSBUVIR + LEDIPASVIR ZYDUS* Dec-15 15 10
TENLIMAC TENELIGLIPTIN MACLEODS Dec-15 14 11
TENIVA TENELIGLIPTIN INTAS Oct-15 14 6

13. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
Jun-17
BRAND SUBGROUP COMPANY LD MAT VAL INCRE VAL
NI BRANDS(LAST 24 MONTHS) 4525 3344
REVITAL H WOMAN GINSENG PRODUCTS SUN* Jan-16 14 8
TRULICITY DULAGLUTIDE ELI LILLY Mar-16 13 12
AZTOLET ATORVASTATIN + CLOPIDOGREL SUN* Aug-15 13 7
LOMOFEN PLUS LOPERAMIDE RPG Apr-16 12 11
SOFAB LP SOFOSBUVIR + LEDIPASVIR SUN* Jan-16 12 5
HEPAGLAN OTHER HEPARINS GLAND May-16 12 11
ROZAGOLD ASPIRIN + ROSUVASTATIN + CLOPIDOGREL SUN* Apr-16 12 11
MACTOTAL OMEGA FATTY ACIDS MACLEODS Dec-15 11 7
MEROFIC PLUS MEROPENEM GUFIC BIOSCIENCE Aug-15 11 8
FIBRISTAL ULIPRISTAL ACETATE AKUMENTIS Nov-15 11 8
ACOGUT ACOTIAMIDE LUPIN Aug-16 11 11
MYCHIRO MYO-INOSITOL + D-CHIROINOSITOL USV Apr-16 11 10
TGLIP TENELIGLIPTIN INTAS Oct-15 11 6
IXAROLA RIVAROXABAN ZYDUS* Oct-15 11 9
ETERNEX T TENELIGLIPTIN ALEMBIC Oct-15 11 6
OSTERI TERIPARATIDE EMCURE* Jul-16 11 11
LOFTAIR GLYCOPYRROLATE + INDACATEROL LUPIN Dec-15 11 7
EASY SIX ALL OTHER VACCINES PANACEA Apr-17 11 11
ENSURE PLUS OTHER NUTRIENTS ABBOTT* Oct-15 11 9
CEASTRA ITRACONAZOLE EMCURE* Sep-16 11 11
6325 Brands launched in last 24 months…

14. Dataset : PharmaTrac MAT JUN 2017